Figure 5
From: The disulfidptosis-related signature predicts prognosis and immune features in glioma patients
Correlation between the disulfidptosis-related signature and immune features. (A) Expression of the cancer‐immunity cycle inhibitory genes between low‐ and high‐risk groups. (B) Expression of FGL2, IL10, TGFB1, and VEGFA between low‐ and high‐risk groups. (C) Immune cell ratio between low‐ and high‐risk groups from TCGA dataset. (D) Distribution of immune subtypes. **p < 0.01, ****p < 0.0001.
